Astria Therapeutics, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 54 rows, 54 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-02-03: Reporting owner PERCEPTIVE ADVISORS LLC | Perceptive Xontogeny Venture Fund, LP | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Xontogeny, LLC | EDELMAN JOSEPH; Form 3; Security Series X Convertible Preferred Stock; Transaction Holding.
- 2021-02-03: Reporting owner PERCEPTIVE ADVISORS LLC | Perceptive Xontogeny Venture Fund, LP | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Xontogeny, LLC | EDELMAN JOSEPH; Form 3; Security Series X Convertible Preferred Stock; Transaction Holding.
- 2021-02-01: Reporting owner EDELMAN JOSEPH | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | PERCEPTIVE ADVISORS LLC | Xontogeny, LLC | Perceptive Xontogeny Venture Fund, LP; Form 4; Security Series X Convertible Preferred Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-02-01: Reporting owner EDELMAN JOSEPH | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | PERCEPTIVE ADVISORS LLC | Xontogeny, LLC | Perceptive Xontogeny Venture Fund, LP; Form 4; Security Series X Convertible Preferred Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-02-03 holding as of filing | PERCEPTIVE ADVISORS LLC | Perceptive Xontogeny Venture Fund, LP | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Xontogeny, LLC | EDELMAN JOSEPH Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series X Convertible Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-03 | ||
| 2021-02-03 holding as of filing | PERCEPTIVE ADVISORS LLC | Perceptive Xontogeny Venture Fund, LP | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Xontogeny, LLC | EDELMAN JOSEPH Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series X Convertible Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2021-02-03 | ||
| 2021-02-01 | EDELMAN JOSEPH | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | PERCEPTIVE ADVISORS LLC | Xontogeny, LLC | Perceptive Xontogeny Venture Fund, LP Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series X Convertible Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,851 4,851 owned after | $3,009.53 | 2021-02-03 | |
| 2021-02-01 | EDELMAN JOSEPH | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | PERCEPTIVE ADVISORS LLC | Xontogeny, LLC | Perceptive Xontogeny Venture Fund, LP Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series X Convertible Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,617 30,920 owned after | $3,009.53 | 2021-02-03 | |
| 2021-02-01 | Callori Fred Director | 4 | Series X Convertible Preferred Stock Derivative · Indirect · By Perceptive Xontogeny Venture Fund, LP | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,617 30,920 owned after | $3,009.53 | 2021-02-03 | |
| 2021-02-01 holding as of filing | Violin Jonathan Director | 3 | Series X Convertible Preferred Stock Derivative · Indirect · By Lazarus Life Sciences I, LLC | Holding | no price filed | 2021-02-01 | ||
| 2021-02-01 holding as of filing | Callori Fred Director | 3 | Series X Convertible Preferred Stock Derivative · Indirect · By Xontogeny, LLC | Holding | no price filed | 2021-02-01 | ||
| 2021-02-01 holding as of filing | Callori Fred Director | 3 | Series X Convertible Preferred Stock Derivative · Indirect · By Perceptive Xontogeny Venture Fund, LP | Holding | no price filed | 2021-02-01 | ||
| 2015-06-30 | Jirousek Michael Officer (Chief Scientific Officer) | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −856,571 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Jirousek Michael Officer (Chief Scientific Officer) | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −5,261 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | George Jean Director | 4 | Series A Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −8,666,667 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | George Jean Director | 4 | Series B Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −3,910,392 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | George Jean Director | 4 | Series B Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −7,388,491 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | George Jean Director | 4 | Series B Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −1,006,712 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | GALAKATOS NICHOLAS Director, 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −20,800,000 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | GALAKATOS NICHOLAS Director, 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −9,728,971 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Donovan Joanne M. Officer (Chief Medical Officer) | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −5,261 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Clarus Ventures II GP, L.P. | Clarus Lifesciences II, L.P. | Clarus Ventures II, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −20,800,000 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Clarus Ventures II GP, L.P. | Clarus Lifesciences II, L.P. | Clarus Ventures II, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −9,728,971 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | SVLSF V, LLC | SV Life Sciences Fund V Strategic Partners, L.P. | SV LIFE SCIENCES FUND V LP | SV Life Sciences Fund V (GP), LP 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −21,218,253 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | SVLSF V, LLC | SV Life Sciences Fund V Strategic Partners, L.P. | SV LIFE SCIENCES FUND V LP | SV Life Sciences Fund V (GP), LP 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −448,414 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | SVLSF V, LLC | SV Life Sciences Fund V Strategic Partners, L.P. | SV LIFE SCIENCES FUND V LP | SV Life Sciences Fund V (GP), LP 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −9,821,385 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | SVLSF V, LLC | SV Life Sciences Fund V Strategic Partners, L.P. | SV LIFE SCIENCES FUND V LP | SV Life Sciences Fund V (GP), LP 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −207,558 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Modi Rick Officer (Chief Business Officer) | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −52,614 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Milne Jill C. Director, Officer (President and CEO) | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −856,548 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Milne Jill C. Director, Officer (President and CEO) | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −105,229 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | MedImmune Ventures, Inc. 10% Owner | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −13,866,666 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | MedImmune Ventures, Inc. 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −4,241,780 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Laufer Ron Director, 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −13,866,666 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-30 | Laufer Ron Director, 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −4,241,780 0 owned after | $0.00 | 2015-06-30 | |
| 2015-06-24 holding as of filing | SV Life Sciences Fund V Strategic Partners, L.P. | SV Life Sciences Fund V (GP), LP | SV LIFE SCIENCES FUND V LP | SVLSF V, LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | SV Life Sciences Fund V Strategic Partners, L.P. | SV Life Sciences Fund V (GP), LP | SV LIFE SCIENCES FUND V LP | SVLSF V, LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | SV Life Sciences Fund V Strategic Partners, L.P. | SV Life Sciences Fund V (GP), LP | SV LIFE SCIENCES FUND V LP | SVLSF V, LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | SV Life Sciences Fund V Strategic Partners, L.P. | SV Life Sciences Fund V (GP), LP | SV LIFE SCIENCES FUND V LP | SVLSF V, LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Modi Rick Officer (Chief Business Officer) | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Milne Jill C. Director, Officer (President and CEO) | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Milne Jill C. Director, Officer (President and CEO) | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | MedImmune Ventures, Inc. 10% Owner | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | MedImmune Ventures, Inc. 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Laufer Ron Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Laufer Ron Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Jirousek Michael Officer (Chief Scientific Officer) | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Jirousek Michael Officer (Chief Scientific Officer) | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | George Jean Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | George Jean Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | George Jean Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | George Jean Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | GALAKATOS NICHOLAS Director, 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | GALAKATOS NICHOLAS Director, 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Donovan Joanne M. Officer (Chief Medical Officer) | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Clarus Lifesciences II, L.P. | Clarus Ventures II GP, L.P. | Clarus Ventures II, LLC 10% Owner | 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Clarus Lifesciences II, L.P. | Clarus Ventures II GP, L.P. | Clarus Ventures II, LLC 10% Owner | 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Advanced Technology Ventures VIII LP | ATV Associates VIII, L.L.C. 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 | ||
| 2015-06-24 holding as of filing | Advanced Technology Ventures VIII LP | ATV Associates VIII, L.L.C. 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2015-06-24 |